Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2010-10-15
pubmed:abstractText
Mechanisms of action and resistance of histone deacetylase inhibitors (HDACIs) are not well understood. A gene expression analysis performed in a phase 1 trial of vorinostat in leukemia indicated that overexpression of genes involved in antioxidant defense was associated with clinical resistance. We hypothesized that nonepigenetic mechanisms may be involved in resistance to HDACI therapy in leukemia. Here we confirmed up-regulation of a series of antioxidants in a pan-HDACI-resistant leukemia cell line HL60/LR. Vorinostat induced reactive oxygen species (ROS) through nicotinamide adenine dinucleotide phosphate oxidase in leukemia cells. An increase in ROS resulted in translocation of nuclear factor E2-related factor 2 from cytosol to nucleus, leading to up-regulation of antioxidant genes, including a majority of glutathione-associated enzymes as a cellular protective mechanism. Addition of ?-phenylethyl isothiocyanate, a natural compound capable of depleting cellular glutathione, significantly enhanced the cytotoxicity of vorinostat in leukemia cell lines and primary leukemia cells by inhibiting the cytoprotective antioxidant response. These results suggest that ROS plays an important role in action of vorinostat and that combination with a redox-modulating compound increases sensitivity to HDACIs and also overcomes vorinostat resistance. Such a combination strategy may be an effective therapeutic regimen and have potential clinical application in leukemia.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
14
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2732-41
pubmed:dateRevised
2011-9-22
pubmed:meshHeading
pubmed-meshheading:20566897-Antioxidants, pubmed-meshheading:20566897-Base Sequence, pubmed-meshheading:20566897-Cell Line, Tumor, pubmed-meshheading:20566897-Cell Survival, pubmed-meshheading:20566897-DNA Primers, pubmed-meshheading:20566897-Drug Resistance, Neoplasm, pubmed-meshheading:20566897-Drug Synergism, pubmed-meshheading:20566897-Enzyme Activation, pubmed-meshheading:20566897-Gene Expression Regulation, Neoplastic, pubmed-meshheading:20566897-HL-60 Cells, pubmed-meshheading:20566897-Histone Deacetylase Inhibitors, pubmed-meshheading:20566897-Humans, pubmed-meshheading:20566897-Hydroxamic Acids, pubmed-meshheading:20566897-Isothiocyanates, pubmed-meshheading:20566897-Leukemia, pubmed-meshheading:20566897-Leukemia, Myeloid, pubmed-meshheading:20566897-NADPH Oxidase, pubmed-meshheading:20566897-NF-E2-Related Factor 2, pubmed-meshheading:20566897-Oxidation-Reduction, pubmed-meshheading:20566897-Reactive Oxygen Species, pubmed-meshheading:20566897-Tumor Cells, Cultured, pubmed-meshheading:20566897-U937 Cells
pubmed:year
2010
pubmed:articleTitle
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate.
pubmed:affiliation
Departments of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't